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Abstract
Purpose To determine to what extent automatically mea-
sured volumetric mammographic density influences screen-
ing performance when using digital mammography (DM).
Methods We collected a consecutive series of 111,898 DM
examinations (2003–2011) from one screening unit of the
Dutch biennial screening program (age 50–75 years). Volu-
metric mammographic density was automatically assessed
using Volpara. We determined screening performance mea-
sures for four density categories comparable to the American
College of Radiology (ACR) breast density categories.
Results Of all the examinations, 21.6% were categorized
as density category 1 (‘almost entirely fatty’) and 41.5,
28.9, and 8.0% as category 2–4 (‘extremely dense’),
respectively. We identified 667 screen-detected and 234
interval cancers. Interval cancer rates were 0.7, 1.9, 2.9,
and 4.4% and false positive rates were 11.2, 15.1, 18.2, and
23.8% for categories 1–4, respectively (both p-
trend\ 0.001). The screening sensitivity, calculated as the
proportion of screen-detected among the total of screen-
detected and interval tumors, was lower in higher density
categories: 85.7, 77.6, 69.5, and 61.0% for categories 1–4,
respectively (p-trend\ 0.001).
Conclusions Volumetric mammographic density, auto-
matically measured on digital mammograms, impacts
screening performance measures along the same patterns as
established with ACR breast density categories. Since
measuring breast density fully automatically has much
higher reproducibility than visual assessment, this auto-
matic method could help with implementing density-based
supplemental screening.
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Introduction
Breast density increases breast cancer risk [1, 2]. In addi-
tion, sensitivity of screening mammography is lower for
women with dense breasts, caused by the masking effect of
dense (fibroglandular) breast tissue [3, 4]. This has led to
breast density legislation in 28 states of the United States of
America (USA) until now, and has fueled ongoing dis-
cussions on the need for supplemental screening for women
with dense breasts worldwide [5].
One hoped that screening performance in women with
dense breasts would improve when film-screen mammog-
raphy (FSM) was replaced by digital mammography (DM).
Unfortunately, screening sensitivity was still worse in
women with dense compared to nondense breasts when
DM was used [6–8]. Most large studies looking into the
effect of breast density on screening performance used the
breast imaging reporting and data system (BI-RADS) for
breast density assessment, which is assessed by radiolo-
gists. However, this method has a moderate inter-observer
agreement [9–12].
With the advent of digital mammography, several fully
automatic volumetric density assessment methods have
been developed. Volpara is one of these methods, and has
shown correlation with BI-RADS density categories and
MRI breast density measurements [13–16].
The effect of automatically measured volumetric breast
density on screening sensitivity has only been studied once
[17]. However, information about the effect of automati-
cally measured volumetric breast density on other screen-
ing performance measures like recall rates, false positive
rates, and positive predictive values (PPV) was not given in
this study. Therefore, the aim of this study was to examine
to what extent automatically measured volumetric mam-
mographic density affected screening sensitivity and other
screening performance measures in a large Dutch popula-
tion-based screening program cohort containing a consec-
utive series of digital screening mammograms and
complete information about interval cancers.
Materials and methods
Study population
Data were acquired from a breast cancer screening unit
(Preventicon screening unit 19, Utrecht, the Netherlands) of
the Foundation of Population Screening Mid-West, one of
the five screening regions of the Dutch breast cancer
screening program. Women participating in this biennial
screening program are aged 50–75. The program involves
mammography only, and all mammograms are read by two
certified screening radiologists. In the Dutch screening pro-
gram, previous screening mammograms are most of the time
available for comparison in case of subsequent screens.
In 2003, DM was introduced at the Preventicon screen-
ing unit [18–20]. Analog mammography systems were
gradually replaced by digital ones. In July 2007, almost all
mammograms at this screening unit were digital [19].
By participating in the Dutch screening program,
women consent to their data being used for evaluation and
improvement of the screening, unless they have indicated
otherwise.
Data collection
We prospectively collected all unprocessed DM examina-
tions that were taken at the Preventicon screening unit
between 2003 and 2011, with exception of a 4-month
period in 2009 when only processed data were archived.
All mammograms were acquired using Lorad Selenia DM
systems (Hologic, Danbury, Conn.). The first screening
examination of a woman in the screening program always
included the two standard views, craniocaudal (CC) and
mediolateral oblique (MLO). At subsequent screening
examinations, MLO was the routinely acquired view and
CC was acquired in 57% of the cases by indication (e.g.,
high breast density, visible abnormality) during the study
period. Recall and breast cancer detection information was
obtained from the screening registration system. Interval
cancers were identified through linkage with the Nether-
lands Cancer Registry.
Examinations were excluded, when information about
recall or final outcome was missing. In addition, exami-
nations for which breast density could not be determined,
and interval cancers diagnosed more than 24 months after
the last screening mammogram were excluded for analysis.
Tumor information such as maximum diameter, nodal
status, and ICD-O codes were obtained from the screening
registration system. Nodes were classified negative when
the sentinel lymph node, or the dissection specimen in case
no sentinel lymph node procedure was performed, con-
tained no or only isolated tumor cells. Nodes were con-
sidered positive if they contained micrometastases
(0.2–2 mm) or metastases larger than 2 mm.
Volumetric mammographic density assessment
Percentage dense volume (PDV) was automatically asses-
sed from unprocessed mammograms of the left and right
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breasts, and MLO and CC views using the commercially
available Volpara Density software (version 1.5.0, Volpara
Solutions, Wellington, New Zealand) [21].
The average PDV per screening examination was
determined using the available views of both breasts.
Volpara density grades (VDGs) were constructed based on
this average PDV (VDG1: 0% B VBD\ 4.5%, VDG2:
4.5% B VBD\ 7.5%, VDG3: 7.5% B VBD\ 15.5%,
VDG4: VBD C 15.5%). The VDGs are designed to mimic
the American College of Radiology (ACR) BI-RADS
breast density categories (4th edition).
Statistical analysis
Examinations were grouped according to VDGs. Within
these groups, we determined the following screening per-
formance measures with accompanying 95% confidence
intervals (CI) using generalized estimating equations
(GEE) to account for correlation between examinations of
the same woman using the ‘independence’ correlation
structure: recall rate, false positive rate, screen-detected
breast cancer rate, interval breast cancer rate, total breast
cancer rate (all rates are per 1000 screening examinations),
sensitivity and specificity of the screening, and positive
predictive value (PPV). For the screening sensitivity, we
calculated Wilson’s 95% confidence intervals (see Table 1
for screening performance definitions). For comparison
with American screening programs, we also determined
interval cancer rates for the first year after a negative
screening mammogram, since the screening interval in the
USA is normally 1 year.
We performed several sensitivity analyses: (1) taking
only invasive tumors into account (i.e., excluding the
examinations leading to a true positive or false negative
diagnosis of in situ carcinoma); (2) taking only subsequent
screening rounds into account, since performance measures
are expected to be different between first and subsequent
rounds (in case of subsequent rounds, the prior mammo-
gram could be analog or digital); (3) using VDGs based on
the mean PDV of only the MLO views instead of using all
available views.
We tested for linear trends across the four density cat-
egories for screening performance measures, the percent-
age of in situ cancers, and positive lymph nodes with a Chi
square linear trend test. In addition, we examined whether
tumors diagnosed in dense breasts were larger than in
nondense breasts, using the Jonckheere-Terpstra test, as we
expected tumor size not to be normally distributed. All
statistical tests were two-sided. Statistical analyses were
performed in IBM SPSS statistics, version 21 and in R,
version 3.2.2 using the ‘‘geese’’ function from the ‘‘geep-
ack’’ package.
Results
In total, 113,956 screening examinations were available.
We excluded 50 examinations of which the screening
outcome was unknown, 47 interval cancers which were
diagnosed more than 24 months after the last screening
examination, and 1961 examinations for which VDG could
not be assessed. This resulted in 111,898 examinations
belonging to 53,239 women with a median age of 58 years
(IQR: 53–64 years). Among the examinations, 21.6% were
categorized as density category 1 (‘almost entirely fatty’),
and 41.5, 28.9, and 8.0% as category 2–4 (‘extremely
Table 1 Definitions of screening performance measures
FN (Interval breast cancer) Breast cancers diagnosed within 24 months after a screening examination that did not lead to recall (negative
mammogram), and before the next scheduled screening examination
TP (Screen-detected breast
cancer)
Breast cancers diagnosed after a recalled screening examination (positive mammogram)
FP Screening examinations that led to a recall (positive mammogram), but not to a breast cancer diagnosis within
24 months after the examination, or before the next scheduled screening examination
TN Screening examinations that did not lead to recall (negative mammogram) and no breast cancer was diagnosed
within 24 months after the examination, or before the next scheduled screening examination
Sensitivity of screening The number of screen-detected breast cancers divided by the total number of screen-detected plus interval breast
cancers ((TP/(TP ? FN))
Specificity of screening Number of screening examinations that did not lead to recall (negative mammogram) and no breast cancer
diagnosis within 24 months, or before the next scheduled screening examination divided by the total number of
examinations without breast cancer diagnosis within 24 months, or before the next scheduled screening
examination ((TN/(TN ? FP))
PPV The number of screen-detected breast cancers divided by the total number of examinations that led to recall ((TP/
(TP ? FP))
FN false negative, TP true positive, FP false positive, TN true negative, PPV positive predictive value
Breast Cancer Res Treat
123
dense’), respectively (Table 2). In total, 667 screen-de-
tected breast cancers were identified based on a mammo-
gram taken before January 1, 2012, and 234 interval
cancers were identified within 24 months after a mammo-
gram taken before January 1, 2012, of which 79.5 and
97.9%, respectively, were invasive breast cancers
(Tables 2, 4).
Screening performance across volumetric density
categories
Table 3 shows that total and interval breast cancer rates,
recall rates, and false positive rates were higher in higher
breast density categories compared to lower density cate-
gories, all with a significant linear trend (p-trend\ 0.001).
Screen-detected breast cancer rates were found to be lowest
in the lowest breast density category (4.0 per 1000 exam-
inations (%)) and more comparable across the three
highest breast density categories: 6.4, 6.6, and 6.8%,
respectively (p-trend\ 0.001). The screening sensitivity
was significantly lower (p-trend\ 0.001) in higher breast
density categories: 85.7, 77.6, 69.5, and 61.0% in VDG
categories 1–4, respectively. No significant linear trend
was found for PPV (p-trend = 0.12) (Table 3).
Overall trends for interval cancer rates, recall rates and
false positive rates, screening sensitivity and specificity
were similar when either invasive cancers alone or both
invasive cancer and in situ cancers were taken into account.
However, when restricting the analyses to invasive cancers
only, the screening sensitivity in VDG4 decreased most
notably compared to the screening sensitivity when both
in situ and invasive breast cancers were taken into account.
When only subsequent screening rounds were taken into
account, the overall trends were again similar to the anal-
yses based on both first and subsequent screening exami-
nations (Table 3). The results of the sensitivity analysis,
where PDV was based on MLO views only, did not differ
from those based on all available views (data not shown).
In VDG category 1, 25% of the interval breast cancers
were diagnosed in the first year after screening examina-
tion; in VDG categories 2 and 3, this was 41% and in VDG
category 4 67%. This resulted in interval cancer rates in the
first year after a screening examination of 0.2, 0.8, 1.2, and
2.9% (p-trend\ 0.001) in VDG categories 1, 2, 3, and 4,
respectively.
Tumor characteristics across volumetric density
categories
Of all tumors, 74.0% were screen-detected and 26.0% were
interval cancers. 15.7% of all tumors were in situ and
84.3% were invasive tumors. 89.4% of the in situ tumors
showed microcalcifications on the last screening mammo-
gram. For screen-detected tumors, the highest proportion of
in situ tumors was found in the highest density category (in
VDG4, 32.8% of the screen-detected tumors were in situ
Table 2 Number of mammography examinations in total and within Volpara Density Grade (VDG) categories (based on the available views)
Total VDG 1 VDG 2 VDG 3 VDG 4
Total
Screening examinations [N (%)] 111,898 (100%) 24,210 (21.6%) 46,426 (41.5%) 32,330 (28.9%) 8932 (8.0%)
Screen-detected cancers (N) 667 96 298 212 61
Interval cancers (N) 234 16 86 93 39
False positives (N) 1774 271 700 590 213
True negatives (N) 109,223 23,827 45,342 31,435 8619
Only invasive tumors taken into account
Screening examinations [N (%)] 111,754 (100%) 24,188 (21.6%) 46,375 (41.5%) 32,279 (28.9%) 8912 (8.0%)
Screen-detected cancers (N) 529 75 250 163 41
Interval cancers (N) 228 15 83 91 39
False positives (N) 1774 271 700 590 213
True negatives (N) 109,223 23,827 45,342 31,435 8619
Only subsequent screening rounds
Screening examinations [N (%)] 94,665 (100%) 22,146 (23.4%) 40,664 (43.0%) 25,777 (27.2%) 6078 (6.4%)
Screen-detected cancers (N) 521 86 249 152 34
Interval cancers (N) 203 16 81 80 26
False positives (N) 1170 214 491 366 99
True negatives (N) 92,771 21,830 39,843 25,179 5919
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tumors) and the lowest proportion in density category 2 (in
VDG2, 15.8% of the screen-detected tumors were in situ
tumors). A significant linear trend was observed for the
proportion of invasive tumors over breast density cate-
gories among screen-detected tumors (p-trend = 0.03).
About 80% of the screen-detected and slightly over 50%
of the interval invasive breast cancers were smaller than
20 mm (pT1 status) at diagnosis. No linear trend was found
for screen-detected tumor size across the four density cat-
egories (p-trendSD = 0.10) (Table 4). Lymph nodes were
positive in 29.3% of the screen-detected cancers and 36.8%
of the interval cancers. For lymph node status, no linear
trend was found across the four breast density categories
for screen-detected breast cancers (p-trendSD = 0.08)
(Table 4).
Discussion
We found that the sensitivity of a DM screening program
was significantly lower in women with high volumetric
breast density than in women with low volumetric breast
density (61.0 and 85.7%, respectively, (p-trend\ 0.001)).
This is despite the higher recall rates in women with high
compared to low breast density (30.7 and 15.2%, respec-
tively) (p-trend\ 0.001).
A study of Destounis et al., which was recently pub-
lished, also studied the screening sensitivity in four auto-
matically determined volumetric breast density categories.
They found screening sensitivities of 95, 89, 83, and 65%
in density categories 1–4, respectively. Additionally, they
determined the mammographic screening sensitivity across
Table 3 Screening performance measures in total and within volpara density grade (VDG) categories (based on the available views)
Screening performance measures (95% CI) for total population and within VDG breast density
categories
p trend
Total VDG 1 VDG 2 VDG 3 VDG 4
Total
Recall/1000 21.8 (20.9; 22.7) 15.2 (13.7; 16.8) 21.7 (20.2; 22.9) 24.8 (23.1; 26.6) 30.7 (27.2; 34.5) \0.001
FP/1000 15.9 (15.1; 16.6) 11.2 (9.9; 12.6) 15.1 (14.0; 16.2) 18.2 (16.8; 19.8) 23.8 (20.8; 27.3) \0.001
Screen-detected cancer/1000 6.0 (5.5; 6.4) 4.0 (3.2; 4.8) 6.4 (5.7; 7.2) 6.6 (5.7; 7.5) 6.8 (5.3; 8.8) \0.001
Interval cancer/1000 2.1 (1.9; 2.4) 0.7 (0.4; 1.1) 1.9 (1.5; 2.3) 2.9 (2.3; 3.5) 4.4 (3.2; 6.0) \0.001
BC/1000 8.1 (7.6; 8.7) 4.6 (3.8; 5.6) 8.3 (7.5; 9.1) 9.4 (8.4; 10.5) 11.2 (9.2; 13.6) \0.001
Sensitivity of screening (%) 74.0 (71.1; 76.7) 85.7 (78.1; 91.0) 77.6 (73.2; 81.5) 69.5 (64.1; 74.4) 61.0 (51.2; 70.0) \0.001
Specificity (%) 98.4 (98.3; 98.5) 98.9 (98.7; 99.0) 98.5 (98.4; 98.6) 98.2 (98.0; 98.3) 97.6 (97.2; 97.9) \0.001
PPV (%) 27.3 (25.6; 29.1) 26.2 (21.9; 30.9) 29.9 (27.1; 32.8) 26.4 (23.5; 29.6) 22.3 (17.7; 27.6) 0.12
Only invasive tumors taken into account
Recall/1000 20.6 (19.8; 21.4) 14.3 (12.9; 15.9) 20.5 (19.2; 21.8) 23.3 (21.7; 25.1) 28.5 (25.2; 32.3) \0.001
FP/1000 15.9 (15.1; 16.6) 11.2 (9.9; 12.6) 15.1 (14.0; 16.3) 18.3 (16.9; 19.8) 23.9 (20.9; 27.4) \0.001
Screen-detected cancer/1000 4.7 (4.3; 5.1) 3.1 (2.5; 3.9) 5.4 (4.8; 6.1) 5.0 (4.3; 5.9) 4.6 (3.4; 6.2) 0.02
Interval cancer/1000 2.1 (1.9; 2.4) 0.6 (0.4; 1.0) 1.8 (1.4; 2.2) 2.8 (2.3; 3.5) 4.4 (3.2;6.0) \0.001
BC/1000 6.9 (6.4; 7.3) 3.7 (3.0; 4.6) 7.2 (6.5; 8.0) 7.9 (7.0; 8.9) 9.0 (7.2; 11.1) \0.001
Sensitivity of screening (%) 69.1 (66.5; 73.0) 83.3 (74.3; 89.6) 74.4 (70.2; 79.4) 62.9 (58.1; 69.8) 50.6 (40.5; 61.9) \0.001
Specificity (%) 98.4 (98.3; 98.5) 98.9 (98.7; 99.0) 98.5 (98.4; 98.6) 98.2 (98.0; 98.3) 97.6 (97.2; 97.9) \0.001
PPV (%) 23.0 (21.3; 24.7) 21.7 (17.6; 26.3) 26.3 (23.6; 29.2) 21.6 (18.9; 24.7) 16.1 (12.1; 21.2) 0.02
Only subsequent screening rounds taken into account
Recall/1000 17.9 (17.0; 18.7) 13.5 (12.1; 15.2) 18.2 (16.9; 19.5) 20.1 (18.4; 21.9) 21.9 (18.5; 25.9) \0.001
FP/1000 12.4 (11.7; 13.1) 9.7 (8.4; 11.0) 12.1 (11.1; 13.2) 14.2 (12.8; 15.7) 16.3 (13.3; 19.9) \0.001
Screen-detected cancer/1000 5.5 (5.0; 6.0) 3.9 (3.1; 4.8) 6.1 (5.4; 6.9) 5.9 (5.0; 6.9) 5.6 (4.0; 7.8) 0.02
Interval cancer/1000 2.2 (1.9; 2.5) 0.7 (0.4; 1.2) 2.0 (1.6; 2.5) 3.1 (2.5; 3.9) 4.3 (2.9; 6.3) \0.001
BC/1000 7.7 (7.2; 8.3) 4.6 (3.8; 5.6) 8.1 (7.3; 9.0) 9.0 (7.9; 10.2) 9.9 (7.7; 12.7) \0.001
Sensitivity of screening (%) 71.3 (68.6; 75.1) 84.3 (76.0; 90.1) 74.8 (70.1; 79.8) 64.4 (59.2; 71.3) 56.7 (44.1; 68.4) \0.001
Specificity (%) 98.8 (98.7; 98.8) 99.0 (98.9; 99.2) 98.8 (98.7; 98.9) 98.6 (98.4; 98.7) 98.4 (98.0; 98.7) \0.001
PPV (%) 30.8 (28.6; 33.0) 28.7 (23.8; 34.0) 33.6 (30.3; 37.1) 29.3 (25.6; 33.4) 25.6 (18.8; 33.7) 0.35
FP false positive examinations, BC breast cancers, PPV positive predictive value. BC/1000 = (Screen-detected cancers/1000) ? (Interval
cancers/1000), Sensitivity of screening = screen-detected cancers/(screen-detected cancers ? interval cancers), Specificity = true negative
examinations/(true negative examinations ? false positive examinations), PPV = screen-detected cancers/(screen-detected cancers ? false
positive examinations)
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the visual BI-RADS categories and found sensitivities of
82% in the lowest and 66% in the highest breast density
category [17].
Four other studies where breast density was visually
assessed on digital screening mammograms, also found a
negative influence of breast density on screening sensitivity
[6–8, 22] a fifth study did not find this result [23].
A Canadian study showed a lower screening sensitivity for
women with 75% or higher breast density (74.2% (95% CI
67.2–80.4)) compared to women with less than 75% breast
density (80.2% (95% CI 78.4–81.9)) when using direct
radiography (DR) in a biennial screening program, where
women who are considered to be at increased risk were
screened annually [8]. In the American Digital Mammo-
graphic Imaging Screening Trial (DMIST), the screening
sensitivity was determined for women with dense and
nondense breasts for several subgroups. Sensitivity seemed
higher for all nondense compared to dense subgroup
comparisons, with exception of postmenopausal women
aged 50–64 years [6]. In a study using data from the Breast
Cancer Surveillance Consortium (BCSC), Kerlikowske
et al. found that in an annual screening program, DM
screening sensitivity was also significantly lower in the
higher BI-RADS breast density categories than in the lower
BI-RADS categories for women aged 50–74 years [7].
However, in another paper by Kerlikowske et al., also
using BCSC data, no significant differences in screening
sensitivity between breast density categories was found,
when DM was used [23]. Finally, in a recently published
study of Weigel et al., where data of the German biennial
screening program was used, screening sensitivity was
found to be lower in the higher as compared to the lower
breast density categories. In that study, screening sensi-
tivities of 100 and 50% were found for the lowest and the
highest density category, respectively [22].
Although the results in the above studies are not com-
pletely consistent, the majority of them showed that
screening performance is still negatively influenced by
breast density when DM is used instead of FSM. This is
also found in the current study.
Table 4 Tumor characteristics in total and within Volpara Density Grade (VDG) categories (based on the available views)
Total VDG 1 VDG 2 VDG 3 VDG 4 p trend
Proportion invasive tumorsa
Total (N = 898) Invasive [N (%)] 757 (84.3%) 90 (80.4%) 333 (87.2%) 254 (83.6%) 80 (80.0%) 0.49
Screen-detected cancer (N = 665) Invasive [N (%)] 529 (79.5%) 75 (78.1%) 250 (84.2%) 163 (77.3%) 41 (67.2%) 0.03
Interval cancer (N = 233) Invasive [N (%)] 228 (97.9%) 15 (93.8%) 83 (97.6%) 91 (97.8%) 39 (100.0%) 0.20
pT (only invasive tumors)b
Total (N = 700) T1 [N (%)] 503 (71.9%) 70 (81.4%) 231 (73.6%) 153 (66.8%) 49 (69.0%)
T2 [N (%)] 171 (24.4%) 15 (17.4%) 74 (23.6%) 65 (28.4%) 17 (23.9%) 0.02c
T3 & T4 [N (%)] 26 (3.7%) 1 (91.2%) 9 (2.9%) 11 (4.8%) 5 (7.0%)
Screen-detected cancer (N = 511) T1 [N (%)] 404 (79.1%) 63 (85.1%) 195 (79.6%) 116 (75.8%) 30 (76.9%)
T2 [N (%)] 97 (19.0%) 11 (14.9%) 46 (18.8%) 33 (21.6%) 7 (17.9%) 0.14c
T3 & T4 [N (%)] 10 (2.0%) 0 (0.0%) 4 (1.6%) 4 (2.6%) 2 (5.1%)
Interval cancer (N = 189) T1 [N (%)] 99 (52.4%) 7 (58.3%) 36 (52.2%) 37 (48.7%) 19 (59.4%)
T2 [N (%)] 74 (39.2%) 4 (33.3%) 28 (40.6%) 32 (42.1%) 10 (31.3%) 0.87c
T3 and T4 [N (%)] 16 (8.5%) 1 (8.3%) 5 (7.2%) 7 (9.2%) 3 (9.4%)
Lymph node status (only invasive tumors)d
Total (N = 741) Positive [N (%)] 234 (31.6%) 18 (20.2%) 105 (32.3%) 87 (35.2%) 24 (30.0%) 0.12
Screen-detected cancer (N = 518) Positive [N (%)] 152 (29.3%) 13 (17.6%) 75 (30.7%) 51 (32.1%) 13 (31.7%) 0.08
Interval cancer (N = 223) Positive [N (%)] 82 (36.8%) 5 (33.3%) 30 (37.0%) 36 (40.9%) 11 (28.2%) 0.68
Tumor diameter (only invasive tumors)e
Total (N = 691) Median (mm) (IQR) 15 (10; 22) 12 (8; 18) 15 (10; 21) 17 (11; 25) 14 (10; 22) 0.01
Screen-detected cancer (N = 500) Median (mm) (IQR) 13 (9; 19) 11 (8; 17) 13 (10; 19) 14 (10; 20) 12 (8; 19) 0.10
Interval cancer (N = 191) Median (mm) (IQR) 20 (14; 30) 20 (13; 33) 19 (16; 30) 21 (16; 31) 16 (12; 25) 0.34
a Information on invasiveness is missing for 3 tumors (2 screen-detected and 1 interval tumors)
b Information on pT status is missing for 57 tumors (18 screen-detected and 39 interval tumors)
c p-trend determined for T1 versus T2, T3, and T4
d Information on lymph node status is missing for 16 tumors (11 screen-detected and 5 interval tumors)
e Information on tumor diameter is missing for 66 tumors (29 screen-detected and 37 interval tumors)
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Four out of six above-mentioned studies were conducted
in the USA [6, 7, 17, 23]. The only European study
determining the influence of breast density on digital
mammography screening performance was the recently
published study of Weigel et al. [22]. However, our study is
the first to determine the effect of automatically assessed
volumetric mammographic density on DM screening per-
formance in a European population-based screening set-
ting. There are three notable differences between European
and American screening programs: (1) recall rates are
below 5–7% in Europe and around 8–10% in the USA
[23–29]; (2) double-reading, which is also used in this
study, is common in European screening programs, but not
in the USA [30]; (3) the screening interval is different.
Biennial screening is common in European countries, while
in the USA, women are mostly screened yearly [30].
When looking at the interval cancers diagnosed within
the first year after a negative screening mammogram, we
found that in the lower density categories, only a small part
of the interval cancers were found in the first year after a
negative screening examination, and most were found in
the second year, whereas in women with extremely dense
breasts, this was the other way around. Although a one-
year screening interval instead of a 2-year screening
interval would probably result in a higher program sensi-
tivity in all density groups, this will happen to a larger
extent in the women with fatty breasts than in those with
extremely dense breasts, resulting in larger differences in
screening sensitivity across density categories.
When only invasive cancers instead of both invasive and
in situ cancers were taken into account, the screening
sensitivity decreased most notably in VDG4. This indicates
that the detection of invasive breast cancers in DM
screening is hampered to a larger extent than the detection
of in situ breast cancers (Table 3). A possible explanation
for this is that the visibility of microcalcifications, that
often are the hallmark of ductal carcinoma in situ (DCIS)
on mammography [20], is not hampered as much in
dense tissue as the visibility of invasive breast cancers.
89.4% of the DCIS in our study was accompanied by
microcalcifications.
False positive rates were found to be higher in women
with dense breasts compared to women with nondense
breasts. Similar trends were found in two American studies
using BCSC data [7, 31].
When looking at the tumor characteristics of screen-
detected breast cancers, we observe a significant linear
trend for the proportion of invasive tumors over breast
density categories (p-trend = 0.03). In addition, the size of
screen-detected cancers and the proportion of positive
lymph node status among screen-detected cancers seem to
be larger in denser breasts. However, no significant linear
trend was found for screen-detected tumor size and positive
lymph node status proportion across the four density cat-
egories (p-trendsize = 0.10 and p-trendlymph node status =
0.08).
It should be noted that the four density categories
(VDGs) used in this study are comparable to the 4th edition
BI-RADS density categories. Although in 2013 the 5th BI-
RADS density edition was introduced, we here still used
the VDG categories comparable to the 4th edition, to
enable better comparison with previous studies.
A limitation of this study is that during the study period,
the MLO view was the standardly acquired view for the
subsequent screening rounds and CC views were only
taken in addition to MLO during the first screening round
or by indication during subsequent rounds. As a result,
breast density was determined based on only MLO views
for some examinations and on both MLO and CC views for
other examinations in our main analysis. Volpara’s PDV
measured on CC views tends to be somewhat higher than
on MLO views [32]. As CC views are more often per-
formed among women with dense breasts and women with
a suspicious region on their MLO view, breast density
might be somewhat artificially elevated for these women.
Our sensitivity analysis using VDG categories based on
PDV from the MLO views only did not lead to different
conclusions. Screening sensitivity is presumably higher
when both MLO and CC views are available compared to
MLO views only. Therefore, standardly taking both MLO
and CC views would lead to higher sensitivity, particularly
in women with fatty breasts as they are the ones who most
often receive MLO views only. This would lead to larger
differences in screening performance across breast density
categories.
Strengths of this study are the large sample size and the
fact that the digital mammograms were acquired in routine
screening. In addition, we used a fully automatic method to
determine PDV, which was possible because unprocessed
image data were archived. In several studies, this automatic
method (Volpara) showed to be correlated with BI-RADS
breast density and to give comparable breast cancer risk
estimations as with BI-RADS breast density [13, 15, 16]. In
addition, it has been validated against MRI [14]. Volpara
gives objective and reproducible density measurements,
representing the amount of dense tissue rather than the size
of the dense tissue projection as measured by area-based
methods.
In summary, in a large screening population, where DM
was used for screening and a fully automatic method
(Volpara) was used to determine PDV, breast density was
found to significantly hamper the detection of breast
tumors. This is shown by a lower screening sensitivity in
women with dense compared to those with nondense
breasts, which existed despite a higher recall rate for
women with dense breasts. These findings are in line with
Breast Cancer Res Treat
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results of most studies using visually assessed BI-RADS
density on digital mammograms. Since measuring breast
density fully automatically has higher reproducibility than
visual assessment, this automatic method could help with
facilitating a more tailored screening, such as supplemental
screening for women with dense breasts.
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